2,3,4-trichlorobut-1-ene

Carcinogenicity

Administrative data

Endpoint:

carcinogenicity: inhalation

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

4 (not assignable)

Rationale for reliability incl. deficiencies:

other: Original data not available

Data source

Reference

Reference 1

Reference Type:

study report

Title:

Unnamed

Year:

1981

Reference 2

Reference Type:

secondary source

Title:

No information

Author:

!SIDSP*

Year:

1993

Bibliographic source:

OECD/SIDS. Screening Information Data Set (SIDS) of OECD High Production Volume Chemicals Programme, 19, (1993)

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 451 (Carcinogenicity Studies)

GLP compliance:

not specified

Test material

Test material information

Constituent 1

Reference substance name:

2,3,4-trichlorobut-1-ene

EC Number:

219-397-9

EC Name:

2,3,4-trichlorobut-1-ene

Cas Number:

2431-50-7

Molecular formula:

C4H5Cl3

IUPAC Name:

2,3,4-trichlorobut-1-ene

Details on test material:

- Name of test material (as cited in study report): 1-Butene, 2,3,4-trichloro

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Administration / exposure

Route of administration:

inhalation

Type of inhalation exposure (if applicable):

not specified

Vehicle:

not specified

Analytical verification of doses or concentrations:

not specified

Duration of treatment / exposure:

25 months

Frequency of treatment:

6h/d, 5d/w

Post exposure period:

no data

Doses / concentrations

Doses / concentrations 1

Remarks:

Doses / Concentrations:
0.001 and 0.013 mg/L (0.2 and 2.0 ppm)
Basis:
other: Starting doses

Doses / concentrations 2

Remarks:

Doses / Concentrations:
0.001 and 0.010 mg/L (0.2 and 1.5 ppm)
Basis:
other: After 12 weeks high dose was reduced

No. of animals per sex per dose:

55

Control animals:

yes

Details on study design:

Post-exposure period: no

Examinations

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes

Sacrifice and pathology:

GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes

Results and discussion

Results of examinations

Clinical signs:

effects observed, treatment-related

Mortality:

mortality observed, treatment-related

Body weight and weight changes:

effects observed, treatment-related

Food consumption and compound intake (if feeding study):

not specified

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

not specified

Haematological findings:

no effects observed

Clinical biochemistry findings:

no effects observed

Urinalysis findings:

not specified

Behaviour (functional findings):

not specified

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Gross pathological findings:

not specified

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Histopathological findings: neoplastic:

effects observed, treatment-related

Details on results:

Inhalation exposure (6h/d, 5d/w for 25 months) to 1.5 ppm 2,3,4-trichlorobut-1-ene induced nasal tumors in Wistar rats.

CLINICAL SIGNS AND MORTALITY
high dose group: dyspnoea, signs of chronic respiratory disease, growth retardation, increased mortality

HAEMATOLOGY
no effects

CLINICAL CHEMISTRY
no effects

ORGAN WEIGHTS
high dose group: increased rel. lung weights

HISTOPATHOLOGY: NON-NEOPLASTIC
low dose group: inflammatory changes and non-neoplastic alterations of the olfactory epithelium;

HISTOPATHOLOGY: NEOPLASTIC (if applicable)
high dose group: nasal neuroepitheliomas of olfactoneurogenic origin 27 % in males and 18 % in females, 3 % malignant nasal Schwannomas in males (control all these tumors 0 %)
low dose group: no nasal tumors

Effect levels

1

Dose descriptor:

NOAEC

Effect level:

0.2 ppm

Sex:

male/female

Basis for effect level:

other: (0.001 mg/L)

Remarks on result:

other: Effect type: carcinogenicity (migrated information)

2

Dose descriptor:

LOAEC

Effect level:

1.5 ppm

Sex:

male/female

Basis for effect level:

other: (0.010 mg/L) nasal neuroepitheliomas of olfactoneurogenic origin 27 % in males and 18 % in females, 3 % malignant nasal Schwannomas in males

Remarks on result:

other: Effect type: carcinogenicity (migrated information)

Any other information on results incl. tables

Freetext:
haematological and biochemical values not effected
1.5/2.0 ppm (at week 12 dose-level of 2.0 ppm was lowered
to 1.5 ppm up to week 83): dyspnoea, growth retardation,
increased mortality, increased rel. lung weights, signs of
chronic respiratory disease, nasal neuroepitheliomas of
olfactoneurogenic origin 27 % in males and 18 % in females,
3 % malignant nasal Schwannomas in males (control all these
tumors 0 %) 0.2 ppm: inflammatory changes and non-neoplastic
alterations of the olfactory epithelium; no nasal tumors